key: cord-0888216-ae4ig4r7
authors: da Silva, Gustavo Figueiredo; da Silva, Caroline Figueiredo; da Nobrega Oliveira, Raddib Eduardo Noleto; Romancini, Fabiana; Mendes, Rafael Marques; Locks, Amanda; Longo, Maria Francisca Moro; Moro, Carla Heloisa Cabral; Longo, Alexandre Luiz; Braatz, Vera Lucia
title: Response to “Nerve conduction studies support the classification of SARSCoV‐2 associated Guillain‐Barre subtypes”
date: 2022-04-04
journal: Clin Exp Neuroimmunol
DOI: 10.1111/cen3.12696
sha: 0c475bb96470057b2fef59bc1e0dcc5fc51b14b1
doc_id: 888216
cord_uid: ae4ig4r7

-

Dear Editor,

We read with interest the comments made by Finsterer et al. 1 on our previously published case report "Guillain-Barré syndrome after coronavirus disease 2019 vaccine: A temporal association". 2 We understand that the comments made are interesting points of discussion. Therefore, for all the reasons mentioned above and despite the interesting and pertinent comments made by Finsterer et al., the authors adopted a more cautious approach and, thus, defined the case as a temporal association, not necessarily a causal one.

ChAdOx1 COVID-19 vaccine, COVID-19 vaccines, Guillain-Barre syndrome, peripheral nervous system diseases

Nerve conduction studies support the classification of SARS-CoV-2 associated Guillain-Barre subtypes

Guillain-Barré syndrome after coronavirus disease 2019 vaccine: A temporal association

The levels of evidence and their role in evidence-based medicine